| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Celldex Therapeutics (NASDAQ:CLDX) reported its Q4 earnings results on Monday, February 26, 2024 at 07:01 AM.
Here's what investors need to know about the announcement.
Celldex Therapeutics missed estimated earnings by -12.0%, reporting an EPS of $-0.83 versus an estimate of $-0.74.
Revenue was up $2.52 million from the same period last year.
Last quarter the company missed on EPS by $0.13 which was followed by a 8.0% increase in the share price the next day.
Here's a look at Celldex Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.68 | -0.67 | -0.63 | -0.59 |
| EPS Actual | -0.81 | -0.65 | -0.62 | -0.56 |
| Revenue Estimate | 580K | 530K | 410K | 260K |
| Revenue Actual | 1.52M | 268K | 967K | 1.61M |
To track all earnings releases for Celldex Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CLDX
